Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
140 results about "Staphylococcus sciuri" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Staphylococcus sciuri is a Gram-positive, oxidase-positive, coagulase-negative member of the bacterial genus Staphylococcus consisting of clustered cocci. The type subspecies S. sciuri subsp. sciuri was originally used to categorize 35 strains shown to use cellobiose, galactose, sucrose, and glycerol.
Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases
InactiveUS20090191288A1Safe and economical and effectiveGood and consistent resultOrganic active ingredientsBiocideBENZYL ALCOHOL/WATERInfectious illness
An improved method (process) and medicinal composition is provided to treat herpes, pseudomonas, hepatitis, staph (staphylococci) and other infectious diseases The inexpensive medicinal composition can be self-administered and maintained for a prescribed time. The attractive medicinal composition can comprise a quaternary ammonium salt surfactant, a skin protectant and an alcohol. The quaternary ammonium salt surfactant can comprise benzalkonium halide, preferably benzalkonium chloride. The skin protectant can comprise Allantoin. The alcohol can serve as a pain reliever and can comprise benzyl alcohol. The medicinal composition can also include other compounds, additives, herbal extracts and / or carriers.
Owner:SQUIRES MERYL J
Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections
InactiveUS6979446B2Avoid stickingInhibiting or impairing the binding of the ClfA proteinAntibacterial agentsBacterial antigen ingredientsBacteroidesStaphylococcus cohnii
Monoclonal antibodies which can bind to the ClfA protein and which are generated from binding subdomains or active fragments of the ClfA protein from Staphylococcus aureus, including the active fragments proteins from its fibrinogen binding domain such as Clf40 protein, the Clf33 protein, or ClfA N3, are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus aureus. In addition, medical instruments can be treated using the monoclonal antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the antibodies of the present invention are advantageous because they can prevent adherence of the bacteria to host cells by impairing or inhibiting the ability of S. aureus ClfA to bind to fibrinogen or fibrin, and thus can be utilized in methods or treating or preventing staphylococcal inventions.
Owner:INHIBITEX INC
Ketolide Derivatives as Antibacterial Agents
The present invention provides ketolide derivatives, which can be used as antibacterial agents. In particular, compounds described herein can be used for treating or preventing conditions caused by or contributed to by Gram-positive, Gram-negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Moraxalla spp. Chlamydia spp., Mycoplasm, Legionella spp., Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebaclerium, Bacillus or Enterobactericeae. Also provided are processes for preparing such ketolide derivatives, pharmaceutical compositions thereof, and methods of treating bacterial infections.
Owner:RANBAXY LAB LTD
Capsular polysaccharide adhesin antigen, preparation, purification and use
A substantially pure capsular exopolysaccharide adhesin of coagulaso-negative staphylococcal strains, and a general method to prepare such adhesins, are described. Vaccines composed of such adhesins, and uses of such adhesins to produce polyclonal and mono-clonal antibodies against such adhesins, are also disclosed. The adhesins are useful in coating polymeric medical materials to prevent colonization by coagulase-negative staphylococcal strains, and as a probe in selecting desirable polymeric medical materials. Such adhesin antibodies are useful in vivo to prevent infection by noso-comial coagulase-negative staphylococcal strains, in assays for the detection of such bacteria, in assays for the estimation of such adhesins in complex mixtures, and as an affinity chromatography matrix.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC
East-Asia scorpion antibiotic peptide gene and preparation method and application
ActiveCN101063102AHigh antibacterial activitySimple and efficient approach to molecular designAntibacterial agentsBacteriaChemical synthesisCDNA library
The invention discloses a preparing method of east Asia Tityus antibiotic peptide gene and appliance, which comprises the following steps: restructuring bacillus coli Escherichia coli DH5a / BmKAMP1, CCTCC NO: M207036; constructing east Asia Tityus ioterium cell cDNA library; choosing PCR method; sieving positive colony of scorpion antibiotic peptide gene from ioterium cDNA library; sequence-analyzing coding trait of antibiotic peptide gene; assuring amino acid sequence of the antibiotic peptide gene; adopting chemosynthesis antibiotic peptide; possessing inhibition of diverse density for Gram's bacterium. This antibiotic peptide possesses specificity and high active, which can be used as antibacterial drugs.
Owner:唐克煌
Gene drive carrier and construction method thereof
InactiveCN108707620AAvoid getting againElimination of the methicillin resistance geneVector-based foreign material introductionResistant genesCarrier system
The invention belongs to the field of bioengineering and particularly relates to a Gene drive carrier and a construction method thereof. The construction method includes the steps of 1), artificiallysynthesizing a cap5A promoter and an sgRNA fragment; 2), amplifying a cas9 gene; 3), amplifying a plasmid skeleton; 4), amplifying an rpsL promoter; 5), assembling an empty carrier; 6), inserting a spacer targeted at the formula described; 7), constructing the carrier. In the method, a novel chromosome box recombinase CcrC2 and CRISPR-Cas9 technology are combined in an attempting manner, an SCCmeckiller carrier system, namely the Gene driver carrier is constructed, the Gene drive acts on methicillin-resistant staphylococcus aureus MRSA, staphylococcal chromosome box SCCmec is targeted to remove from the methicillin-resistant staphylococcus aureus MRSA, and methicillin-resistant genes are thereby eliminated.
Owner:NORTHWEST A & F UNIV
Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections
InactiveUS20050287164A1Avoid stickingInhibiting or impairing the binding of the ClfA proteinAntibacterial agentsAntibody mimetics/scaffoldsBacteroidesStaphylococcus cohnii
Owner:INHIBITEX INC
Novel staphylophage and composition, as well as preparation methods and application thereof
ActiveCN107779439AEfficient killingNon-toxicAntibacterial agentsViral/bacteriophage medical ingredientsMicroorganismStaphylococcal Phages
The invention relates to the field of microorganisms, and specifically provides a novel staphylophage and a composition, as well as preparation methods and application thereof. The phage is aureus staphylophage J1P1 with the storage number of CCTCC NO: M2016284, aureus staphylophage J1P2 with the storage of CCTCC NO: M2016285, aureus staphylophage J1P3 with the storage of CCTCC NO: M2016286, aureus staphylophage J2-1P1 with the storage of CCTCC NO: M2016287, or aureus staphylophage J2-1P2 with the storage of CCTCC NO: M2016288. The phage is capable of preventing and treating human or animal bacterial infectious diseases caused by various staphylococcocci, particularly by aureus staphylophage; a good phage resource is provided to develop novel antimicrobial preparations; the novel staphylophage has a good application and development prospect.
Owner:PHAGELUX (NANJING) BIO-TECH CO LTD
Method for detecting staphylococcus aureus based on nucleic acid chromatography biosensing technique
InactiveCN107419007AMicrobiological testing/measurementDNA/RNA fragmentationStaphylococcus cohniiVirulent characteristics
The invention relates to a method for detecting staphylococcus aureus based on a nucleic acid chromatography biosensing technique. The method provided by the invention comprises the following steps: designing a loop-mediated isothermal amplification (LAMP) primer (SEQ ID NO:1-4) according to a virulence gene nuc of the staphylococcus aureus, and establishing a staphylococcus aureus detection method based on an LAMP nano enzyme sensor by combining with a nano nucleic acid test strip. The method provided by the invention can be successfully used for distinguishing viable bacterial cells and dead bacterial cells, and lower detection limit on the staphylococcus aureus can reach 10CFU / mL.
Owner:CHINA AGRI UNIV
Method of protecting against staphylococcal infection
InactiveUS20060228368A1Easy to produceAntibody ingredientsImmunoglobulinsAntigenStaphylococcus cohnii
A method of preventing or treating staphylococcal bacterial infection in an individual is disclosed. A vaccine based on a conjugate the 336 polysaccharide antigen can be used for active protection in individuals who are to be subjected to conditions that place them at immediate risk of developing a bacterial infection, as would be case in the context of a catheterization or a surgical procedure. Alternatively, antibodies raised in response to the antigen can be used to treat or to provide passive protection to individuals. The method can be used in a population of patients at risk for infection by various species of Staphylococcus or various types of Staphylococcus aureus.
Owner:GLAXOSMITHKLINE BIOLOGICALS SA
Monoclonal antibodies to the fibronectin binding protein and method of use in treating or preventing infections
InactiveUS7115264B2High affinityAvoid stickingImmunoglobulins against bacteriaEnzymologyBacteroidesStaphylococcus cohnii
Monoclonal antibodies which can bind to the Fnbp protein of Staphylococcus aureus and which are generated from a peptide from the D2 region of fibronectin binding protein B (Fnbp) of S. aureus are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus aureus. The monoclonal antibodies of the invention are advantageous in that they bind S. aureus in high affinity and thus can be useful in the prevention of the adherence of staph bacteria to host cells by impairing or inhibiting the ability of S. aureus Fnbp to bind to fibronectin. Kits and methods of utilizing the monoclonal antibodies of the invention are also provided.
Owner:INHIBITEX INC
Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein
ActiveUS8475798B2High affinityMethod can be usedAntibacterial agentsAntibody ingredientsADAMTS ProteinsMonoclonal antibody
Owner:INHIBITEX INC +1
Ketolide derivatives as antibacterial agents
The present invention provides ketolide derivatives, which can be used as anti-bacterial agents. Compounds disclosed herein can be used for the treating or preventing conditions caused by or contributed to by gram positive, gram negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Moraxalla spp., Chlamydia spp., Mycoplasm, Legionella spp., Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebacterium, Bacillus, Enterobactericeae or any combination thereof. Also provided are processes for preparing compounds disclosed herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods of treating bacterial infections.
Owner:RANBAXY LAB LTD
Expression of recombinant mature lysostaphin
A portion of the lysostaphin gene of Staphylococcus simulans has been cloned and overexpressed in the cytoplasm of E. coli to yield lysostaphin, in the absence of preprolysostaphin and prolysostaphin, under the transcriptional control of an IPTG-inducible promoter and a ribosome binding site. IPTG induction of the transformed host cells produces intracellular, soluble, mature lysostaphin (27 kDa), in the complete absence of preprolysostaphin and prolysostaphin. The mature lysostaphin so formed dose not require post-translational modification. The mature lysostaphin so formed can be used treat and prevent staphylococcal infections.
Owner:COUNCIL OF SCI & IND RES +1
Ketolide Derivatives as Antibacterial Agents
Provided herein are ketolide derivatives, which can be used as antibacterial agents. Compounds described herein can be used for treating or preventing conditions caused by or contributed to by gram positive, gram negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Moraxalla spp., Chlamydia spp., Mycoplasm, Legionella spp., Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebacterium, Bacillus, Enterobactericeae, Propionibacterium acnes or any combination thereof. Also provided are processes for preparation of compounds described herein, pharmaceutical compositions thereof, and methods of treating bacterial infections.
Owner:RANBAXY LAB LTD
Compound preparation for dissolving staphyloase and preparation method
InactiveCN1438032AImprove the bactericidal effectExpanded bactericidal spectrumAntibacterial agentsPeptide/protein ingredientsSide effectMonilinia laxa
The present invention discloses a lysostaphin compounded preparation. Said preparation comprises bacteria-killing effective quantity of lysostaphin and lysozyme. Said lysostaphin compounded preparation has higher bacteria-killing effect as compared with single lysostaphin, not only has the strong bacteria-killing action for Gram-positive bacterium and Gram-negative bacterium, but also has the good effect for killing the fungi of Candida albicans and red trichophyton, etc. It has high bacteria-killing activity and stability, does not produce drug resistance, and has no toxic side effect.
Owner:SHANGHAI HI TECH BIOENG
Uses of smoked plum extract against virus, bacteria, mycoplasma or chlamydia of livestock and poultry
ActiveCN101317904APrevent fluPrevent proliferationAntibacterial agentsAntiviralsBacteroidesSmoked Plum
The present invention discloses the application of ebony extract or effective parts (I, II and III) in preventing and remedying livestock and poultry viral disease, bacterial disease, mycoplasma disease and chlamydia disease. Tests in vitro and in vivo show that the ebony extract or effective parts (I, II and III) have the effects of preventing and inhibiting poultry flu virus, newcastle disease virus, infective bronchitis virus, and the like, and can effectively kill pathogenic bacteria causing the animal disease at the same time, such as bovine streptococcus agalactiae, bovine gold staphylococcus, bovine colon bacillus, chicken colon bacillus, etc. In addition, the ebony extract or effective parts can effectively prevent and remedy the poultry chlamydia disease and mycoplasma disease.
Owner:何诚
52 kda protein from coagulase negative staphylococci and fragments thereof
InactiveUS20030082200A1Inhibit bindingAntibacterial agentsBacteriaPassive ImmunizationsProtein isolate
A protein isolated from Staphylococcus epidermidis having an approximate MW of 52 kD determined by SDS-PAGE and an N-terminal amino acid sequence (SEQ ID NO:1), and antigenic determinant-containing fragments of the protein, optionally coupled to an inert carrier or matrix, are disclosed. Disclosed are also a recombinant DNA molecule coding for the protein or the protein fragments; a vector comprising the DNA molecule or the corresponding RNA molecule; antibodies or antigen-binding peptides recognizing and specifically binding to the protein or protein fragment; use of the protein or protein fragment, or the vector, for the production of vaccines against Staphylococcal infections; use of the antibodies or antigen-binding peptides for the production of a medicament for passive immunization; a vaccine against Staphylococcal infections comprising the protein or protein fragment, or the vector, a medicament for passive immunization comprising the antibodies or antigen-binding peptides; and a method of prophylactic and / or therapeutic treatment of Staphylococcal infections.
Owner:BIOSTAPRO
Lysostaphin freeze dried powder used for preventing and treating cattle edometritis
ActiveCN1911441AImprove the bactericidal effectImprove stabilityPowder deliveryPeptide/protein ingredientsPhosphateFreeze-drying
A freeze-dried powder-injection of staphylococcus lysozyme for preventing and treating the endometritis of cow and the skin mucosa infection of other animals, and cleaning and restoring the postpartum uterus of cow is composed of staphylococcus lysozyme, bovine serum albumin, glycine, mannitol, and phosphate. Its preparing process is also disclosed.
Owner:昆山博青生物科技有限公司
Composition and method for vancomycin oral liquid
The invention relates to stable vancomycin hydrochloride powder for oral liquid formulations. Also provided herein are methods of using vancomycin oral liquid formulations for the treatment of certain diseases such as Clostridium difficile pseudomembranous colitis and Staphylococcal enterocolitis as well as kits and related products thereof.
Owner:AZURITY PHARMA INC
Staphylococcus tryptophanyl-tRNA synthetase inhibitor
InactiveCN101084895AInhibitory activityLittle effect on activityAntibacterial agentsHeterocyclic compound active ingredientsBacteroidesDisease
The invention belongs to biological technique field, relates to small molecular inhibitor against staphylococci tryptophanyl-tRNA synthetase (WRS), molecular structure of the inhibitor shown in formula I, method of the inhibitor as medicament for preventive or treating relevant bacterial disease. Biochemical and biological experiments have shown that the inhibitor has strong binding force with target protein staphylococcus epidermidis or Staphylococcus aureus tryptophanyl-tRNA synthetase, can inhibit the activity of the synthetase, inhibit the growth of staphylococcus epidermidis Staphylococcus aureus. It has no toxicity to mammalian cell. The inventive inhibitor can be used for preparing medicament for treating disease caused by staphylococci, and preparing into disinfectant liquid.
Owner:FUDAN UNIV +1
Disinfectant liquid
InactiveCN101390523AGood antibacterial effectLong-acting antibacterialBiocideDisinfectantsDiseaseDisinfectant
The invention discloses a disinfection solution, which is characterized in that the solution has the following components based on weight proportion: 50-100PPM of nano-silver ions, 1-5% of polyvinylpyrrolidone, 1-5% of polyethylene glycol, and the remaining water. As the anti-bacterial rate is up to 99.99%, the invention can effectively kill, resist and inhibit Staphyloccocus aureus Rosenbach, Escherichia coli and other 650 kinds of bacteria and viruses to reduce the spreading rate of disease, and can be used in the disinfection of various environments.
Owner:陈汉洲
Prevention and treatment of streptococcal and staphylococcal infection
InactiveUS20030013643A1Organic active ingredientsBiocideStaphylococcal infectionsStreptococcus mitis
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC
Method for preparing enzyme of dissolving staphylococcal bacteria, its derivative, and method for preparing the derivative
ActiveCN101092618AExpression scheme is simpleSimple purification processBacteriaRecombinant DNA-technologyEscherichia coliProtein target
This invention relates to a method for preparing lysostaphin and its derivatives. The method comprises: designing and synthesizing lysostaphin gene, inserting lysostaphin gene into the digestion site of expression vector (plasmid pET), transforming E. coli, screening positive clones, culturing, inducing the expression of target protein, collecting E. coli, lysing, centrifuging, collecting the supernatant, and purifying the supernatant through chromatography. The method has such advantages as simple process, high expression level, simple purification, high yield, soluble product, and no requirement for renaturation, and is suitable for mass production. The lysostaphin derivatives are obtained by modifying lysostaphin with polyethylene glycol, and have such advantages as low immunogenicity and long half value period. The lysostaphin and its derivatives are suitable for treating Staphylococcus infection in clinic.
Owner:HANGZHOU LION BIOTECH
Broad spectrum antagonists and vaccines directed against pyrogenic exotoxins
InactiveUS7060277B2Avoid problemsBacterial antigen ingredientsPeptide/protein ingredientsT cellBiological activation
The invention relates to peptides comprising an amino acid sequence homologous to the amino sequence of a fragment of a pyrogenic exotoxin, and functional derivatives of said peptides, capable of eliciting protective immunity against toxic shock induced by a pyrogenic exotoxin or by a mixture of pyrogenic exotoxins. Preferred peptides comprise an amino acid sequence homologous to the amino sequence of a fragment of Staphylococcal aureus enterotoxin B (SEB). The invention also relates to broad spectrum pharmaceutical compositions for the treatment, protection against or short term prophylaxis of toxin-mediated activation of T cells, comprising as active ingredient at least one peptide according to the invention or derivative thereof, and to broad spectrum vaccines for conferring long term immunity against toxic shock induced by at least one pyrogenic exotoxin are provided. The vaccines comprising as active ingredient at least one peptide according to the invention, or derivative thereof.
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD
Medicament combination preparation of medicinal compound containing cy-ethyl razepam
The invention relates to medicament combination preparation of medicinal compound taking cy-ethyl razepam medicinal compound containing cy-ethyl razepam or stereoisomer, pro-medicinal, medicinal salt, complex salt or / and salvation as effective constituent. The medicament combination preparation adopts the technical scheme that the cy-ethyl razepam medicinal compound, which has a general formula (1) structure and contains the cy-ethyl razepam or the stereoisomer, the pro-medicinal, the medicinal salt, the complex salt and the solvation, is taken as the effective constituent and forms the medicament combination preparation with a medicament carrier capable of being received on the pharmacy; and the preparation formulation is any preparation formulation said on the pharmacy. The invention also discloses an application of the medicament combination preparation in the process of treating the infection of bacteria taken as gram-positive bacteria like staphylococcus, pneumococcus, enterococcus faecalis, streptococcus, streptococcus bovis, streptococcus pneumoniae, peptostreptococcus, festering streptococcus pneumoniae, festering streptococcus pneumoniae, streptococcus pyogenes, streptococcus agalactiae, viridans streptococci, streptococcus bovis, streptococcus agalactiae B, group green streptococcus, corynebacterium diphtheriae and other bacteria.
Owner:LIAONING LIFENG SCI & TECH DEV
Chemiluminescent enzyme-linked immunoassay detection kit for staphylococcal enterotoxin C
ActiveCN102944678AStrong specificityHigh sensitivityChemiluminescene/bioluminescenceMonoclonal antibodyHorseradish peroxidase
The invention discloses a chemiluminescent enzyme-linked immunoassay detection kit for staphylococcal enterotoxin C. The contents of the kit comprise a staphylococcal enterotoxin C-resistant monoclonal antibody, a horseradish peroxidase-marked staphylococcal enterotoxin C-resistant detection antibody solution, a staphylococcal enterotoxin C series standard solution, a coating solution, a sealing solution, a cleaning solution, a chemiluminescent solution and a chemiluminescent enzyme-linked plate. The kit has the characteristics of high specificity, sensitivity and repeatability, and is suitable for monitoring diseases and quickly and quantitatively detecting staphylococcal enterotoxin C in foods and blood.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Lysostaphin industrial purifying process
This invention discloses a purification technology for lysostaphin industry, which cultures supernatant purified lysostaphins from sphere bacilli containing the lysostaphin gene. Said method includes ionic exchange and drain chromatograph and needs two days only to process 45L sample, the total recovery rate is 50%, the specific activity is greater than 1000V / mg proteins and the purity is over 90% displayed on the non-recovery SDS-PAGE electrophoresis result.
Owner:昆山博青生物科技有限公司
Immune chip for detecting staphylococcal enterotoxin and papaverine and its preparing method
The present invention discloses an immune chip for detecting staphylococcal enterotoxin and papaverina dn its preparation process. The immune chip has slide glass with surface treated with silane as aldehydation reagent and crosslinked with glutaraldehyde as double-function crosslinking reagent, and connected via covalent bond with the molecule of at least one kind of antibody staphylococcal enteriotoxin A antibody, staphylococcal enterotoxin B antibody, staphylococcal enterotoxin C antibody and papaverine antibody. The detection with the immune chip is simple, effective and low in cost.
Owner:INST OF HYGIENE & ENVIRONMENTAL MEDICINE PLA ACAD OF MILITARY MEDICAL
Preparation method of exfoliative toxin C (ExhC) proteins of staphylococcus sciuri
InactiveCN102174553AEfficient expressionImprove biological activityMicroorganism based processesPeptide preparation methodsEscherichia coliHigh concentration
The invention relates to a preparation method of exfoliative toxin C (ExhC) proteins of staphylococcus sciuri, which comprises the following steps of: (1) taking staphylococcus sciuri genome DNA as templates, amplifying the overall length of ExhC genes of the staphylococcus sciuri, and cloning the ExhC genes into prokaryotic expression vectors to obtain recombinant plasmids; (2) performing escherichia coli conversion on the recombinant plasmids, and expressing the recombinant plasmids through IPTG (isopropyl thiogalactoside) induced proteins; and (3) extracting the crude extract of the proteins, and purifying ExhC proteins. In the method, the efficient expression of ExhC in escherichia coli is realized successfully through a gene engineering technology, and high-purity and high-concentration ExhC with biological activities is obtained; moreover, the preparation method is simple to operate and low in cost.
Owner:CHINA AGRI UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com